T-cell engager market size for multiple myeloma
STO-REC-STAT01M2KJT2 National
10 billionUSD
United States · 2032
GSK projects t-cell engager market size for multiple myeloma in United States at 10 billion USD in 2032.
- Publisher
- GSK
- Authority tier
- T2 National
- Locator
- Deal aligned to GSK’s portfolio in blood cancer and approach of acquiring differentiated assets with validated targets
- Retrieved
- 15 Sep 2026
- Status
- Verified
What the source says
The US TCE market for multiple myeloma is expected to exceed $10 billion by 2032.1
Verbatim extraction verified: The figure 10 billion USD is directly attested in the quoted passage (Deal aligned to GSK’s portfolio in blood cancer and approach of acquiring differentiated assets with validated targets).
The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.
- APA
- GSK. (2032). GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences. Retrieved September 15, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-potential-best-in-class-t-cell-engager-tce-for-multiple-myeloma-from-chimagen-biosciences/. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGE
- MLA
- GSK. "GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences." 2032, https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-potential-best-in-class-t-cell-engager-tce-for-multiple-myeloma-from-chimagen-biosciences/. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGE.
- Chicago
- GSK. "GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences." 2032. https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-potential-best-in-class-t-cell-engager-tce-for-multiple-myeloma-from-chimagen-biosciences/. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGE.
- BibTeX
- @misc{gsk2032cellbjmgge, author = {{GSK}}, title = {GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences}, year = {2032}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGE}, note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-potential-best-in-class-t-cell-engager-tce-for-multiple-myeloma-from-chimagen-biosciences/. Accessed September 15, 2026.} }
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Chain of Custody · Verification Audit
Primary Source
- Publisher
- GSK · homepage ↗
- Authority tier
- Tier 2 · National Official
- Report
- GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences
- Type
- Press release
- Published
- —
- Locator
- Deal aligned to GSK’s portfolio in blood cancer and approach of acquiring differentiated assets with validated targets
- Retrieved
- 15 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification & Integrity
- Audit status
- Verified
- Review protocol
- Editorial review
- Checked on
- 15 September 2026
- Last revision
- 15 September 2026
- Archival URI
- /stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGE